biogen_austria_238

EMA recommends Biogen’s MS treatment Zinbryta

pharmafile | May 3, 2016 | News story | Research and Development, Sales and Marketing Biogen, CHMP, EMA, daclizumab, zinbryta 

The Committee for Medicinal Products for Human Use (CMHP) has recommended the granting of a marketing authorisation for Zinbryta (daclizumab) for the treatment of relapsing forms of multiple sclerosis.

Developed by Biogen, Zinbryta is a humanised IgG1 monoclonal antibody that demonstrated statistical significance in the reduction of annualised relapse rate of multiple sclerosis in the DECIDE Phase III trial. In the same trial, a reduction in the number of new or newly enlarging T2-hyperintense lesions was also observed.

The full indication from the European Medicines Agency is: “Zinbryta is indicated in adult patients for the treatment of relapsing forms of multiple sclerosis.” The marketing authorisation from the European Commission is expected to be ratified following the EMA’s recommendation.

Advertisement

Sean Murray

Related Content

Biogen’s high-dose Spinraza regimen receives European Commission approval for spinal muscular atrophy

Biogen’s Spinraza (nusinersen) has received approval from the European Commission (EC) as a new high-dose …

Rethinking oncology trial endpoints with generalised pairwise comparisons

For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …

trial

Biogen and Stoke report positive results for Dravet syndrome drug

Biogen and Stoke Therapeutics have shared encouraging new data for their experimental treatment, zorevunersen, which …

The Gateway to Local Adoption Series

Latest content